Shuwen Debuts it's CODAR-ARMS PCR Liquid Biopsy Technology at ASCO 2018

shuwen logo

Deqing, China, May 17, 2018 / B3C newswire / -- Shuwen Biotech, a leading provider of innovative diagnostic products and medical diagnostic services, announced that studies based on its proprietary high-sensitivity CODAR-ARMS PCR liquid biopsy technology was selected to be published at the annual ASCO 2018. Shuwen’s CODAR-ARMS PCR technology demonstrates superior performance and is being showcased at an international conference for the first time.

The CODAR-ARMS PCR mutation detection technology developed by Shuwen has undergone technological innovations to on one hand, preserve the features of ARMS PCR technology which is recognized to be simple, rapid, and specific, and on the other hand has greatly improved the detection sensitivity of the liquid biopsy assay. The CODAR-ARMS PCR technology simultaneously detects mutations in DNA/RNA from whole blood and further combines efficient sample extraction techniques with optimally modified primers to greatly improve the discrimination between mutant and wild-type gene sequences. The ability to detect mutations at the 0.01% level in a wild-type background can be achieved using an ordinary high-throughput fluorescence quantitative PCR platform.

The study being presented at ASCO took the EGFR T790M mutation as an example, using the CODAR-ARMS PCR technique to detect the EGFR T790M mutation in the blood of drug-resistant lung cancer patients treated with first generation EGFR inhibitors.  EGFR T790M mutation-positive patients were then treated with Osimertinib. In this prospective study, the CODAR-ARMS PCR technique was superior to ddPCR in predicting the efficacy of Osimertinib. This study demonstrated that Shuwen’s CODAR-ARMS PCR technology is more sensitive, more cost-efficient, and has a higher throughput than digital PCR, and most importantly has higher prediction power on drug efficacy. Its applications span companion diagnostics (CDx) for new drug development and for currently available T790M inhibitors.


About ASCO
The American Society of Clinical Oncology (ASCO) was founded in 1964 and is the largest and most influential academic organization of oncology in the world. Many world-class oncologists and participants shared their views on the most cutting-edge clinical oncology research achievements and cancer treatment technologies. Many important research findings and clinical trial results will also be selected for the first time at the ASCO annual meeting. The 2018 ASCO Annual Meeting will be held in Chicago, USA, on June 1-5, 2018.

About Shuwen Biotech
Shuwen Biotech is a China-based diagnostics company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, Max-Plank Institute, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers.  Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.


Dr. Vafa Amirkia
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.